Literature DB >> 28377535

GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects.

Konrad Platzer1, Hongjie Yuan2,3, Hannah Schütz4, Alexander Winschel4, Wenjuan Chen2, Chun Hu2, Hirofumi Kusumoto2, Henrike O Heyne1, Katherine L Helbig5, Sha Tang5, Marcia C Willing6, Brad T Tinkle7, Darius J Adams8, Christel Depienne9,10,11,12, Boris Keren9,10, Cyril Mignot10, Eirik Frengen13, Petter Strømme14, Saskia Biskup15, Dennis Döcker15, Tim M Strom16, Heather C Mefford17, Candace T Myers17, Alison M Muir17, Amy LaCroix17, Lynette Sadleir18, Ingrid E Scheffer19, Eva Brilstra20, Mieke M van Haelst20, Jasper J van der Smagt20, Levinus A Bok21, Rikke S Møller22,23, Uffe B Jensen24, John J Millichap25, Anne T Berg25, Ethan M Goldberg26,27, Isabelle De Bie28, Stephanie Fox28, Philippe Major29, Julie R Jones30, Elaine H Zackai31, Rami Abou Jamra1,32, Arndt Rolfs32, Richard J Leventer33,34, John A Lawson35, Tony Roscioli36, Floor E Jansen37, Emmanuelle Ranza38, Christian M Korff39, Anna-Elina Lehesjoki40,41, Carolina Courage40,41, Tarja Linnankivi42, Douglas R Smith43, Christine Stanley43, Mark Mintz44, Dianalee McKnight45, Amy Decker45, Wen-Hann Tan46, Mark A Tarnopolsky47, Lauren I Brady47, Markus Wolff48, Lutz Dondit49, Helio F Pedro50, Sarah E Parisotto50, Kelly L Jones51, Anup D Patel52,53, David N Franz54, Rena Vanzo55, Elysa Marco56, Judith D Ranells57, Nataliya Di Donato58, William B Dobyns59,60,61, Bodo Laube4, Stephen F Traynelis2,3, Johannes R Lemke1.   

Abstract

BACKGROUND: We aimed for a comprehensive delineation of genetic, functional and phenotypic aspects of GRIN2B encephalopathy and explored potential prospects of personalised medicine.
METHODS: Data of 48 individuals with de novo GRIN2B variants were collected from several diagnostic and research cohorts, as well as from 43 patients from the literature. Functional consequences and response to memantine treatment were investigated in vitro and eventually translated into patient care.
RESULTS: Overall, de novo variants in 86 patients were classified as pathogenic/likely pathogenic. Patients presented with neurodevelopmental disorders and a spectrum of hypotonia, movement disorder, cortical visual impairment, cerebral volume loss and epilepsy. Six patients presented with a consistent malformation of cortical development (MCD) intermediate between tubulinopathies and polymicrogyria. Missense variants cluster in transmembrane segments and ligand-binding sites. Functional consequences of variants were diverse, revealing various potential gain-of-function and loss-of-function mechanisms and a retained sensitivity to the use-dependent blocker memantine. However, an objectifiable beneficial treatment response in the respective patients still remains to be demonstrated.
CONCLUSIONS: In addition to previously known features of intellectual disability, epilepsy and autism, we found evidence that GRIN2B encephalopathy is also frequently associated with movement disorder, cortical visual impairment and MCD revealing novel phenotypic consequences of channelopathies. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  channelopathy; clustering of missense variants; epileptic encephalopathy; pathogenic GRIN2B mutations; precision medicine

Mesh:

Substances:

Year:  2017        PMID: 28377535      PMCID: PMC5656050          DOI: 10.1136/jmedgenet-2016-104509

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  51 in total

Review 1.  The NMDA receptor complex as a therapeutic target in epilepsy: a review.

Authors:  Mehdi Ghasemi; Steven C Schachter
Journal:  Epilepsy Behav       Date:  2011-11-04       Impact factor: 2.937

Review 2.  Glutamate receptor ion channels: structure, regulation, and function.

Authors:  Stephen F Traynelis; Lonnie P Wollmuth; Chris J McBain; Frank S Menniti; Katie M Vance; Kevin K Ogden; Kasper B Hansen; Hongjie Yuan; Scott J Myers; Ray Dingledine
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  Targeted next generation sequencing as a diagnostic tool in epileptic disorders.

Authors:  Johannes R Lemke; Erik Riesch; Tim Scheurenbrand; Max Schubach; Christian Wilhelm; Isabelle Steiner; Jörg Hansen; Carolina Courage; Sabina Gallati; Sarah Bürki; Susi Strozzi; Barbara Goeggel Simonetti; Sebastian Grunt; Maja Steinlin; Michael Alber; Markus Wolff; Thomas Klopstock; Eva C Prott; Rüdiger Lorenz; Christiane Spaich; Sabine Rona; Maya Lakshminarasimhan; Judith Kröll; Thomas Dorn; Günter Krämer; Matthis Synofzik; Felicitas Becker; Yvonne G Weber; Holger Lerche; Detlef Böhm; Saskia Biskup
Journal:  Epilepsia       Date:  2012-05-21       Impact factor: 5.864

4.  Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders.

Authors:  Brian J O'Roak; Laura Vives; Wenqing Fu; Jarrett D Egertson; Ian B Stanaway; Ian G Phelps; Gemma Carvill; Akash Kumar; Choli Lee; Katy Ankenman; Jeff Munson; Joseph B Hiatt; Emily H Turner; Roie Levy; Diana R O'Day; Niklas Krumm; Bradley P Coe; Beth K Martin; Elhanan Borenstein; Deborah A Nickerson; Heather C Mefford; Dan Doherty; Joshua M Akey; Raphael Bernier; Evan E Eichler; Jay Shendure
Journal:  Science       Date:  2012-11-15       Impact factor: 47.728

5.  Delineating the GRIN1 phenotypic spectrum: A distinct genetic NMDA receptor encephalopathy.

Authors:  Johannes R Lemke; Kirsten Geider; Katherine L Helbig; Henrike O Heyne; Hannah Schütz; Julia Hentschel; Carolina Courage; Christel Depienne; Caroline Nava; Delphine Heron; Rikke S Møller; Helle Hjalgrim; Dennis Lal; Bernd A Neubauer; Peter Nürnberg; Holger Thiele; Gerhard Kurlemann; Georgianne L Arnold; Vikas Bhambhani; Deborah Bartholdi; Christeen Ramane J Pedurupillay; Doriana Misceo; Eirik Frengen; Petter Strømme; Dennis J Dlugos; Emily S Doherty; Emilia K Bijlsma; Claudia A Ruivenkamp; Mariette J V Hoffer; Amy Goldstein; Deepa S Rajan; Vinodh Narayanan; Keri Ramsey; Newell Belnap; Isabelle Schrauwen; Ryan Richholt; Bobby P C Koeleman; Joaquim Sá; Carla Mendonça; Carolien G F de Kovel; Sarah Weckhuysen; Katia Hardies; Peter De Jonghe; Linda De Meirleir; Mathieu Milh; Catherine Badens; Marine Lebrun; Tiffany Busa; Christine Francannet; Amélie Piton; Erik Riesch; Saskia Biskup; Heinrich Vogt; Thomas Dorn; Ingo Helbig; Jacques L Michaud; Bodo Laube; Steffen Syrbe
Journal:  Neurology       Date:  2016-05-06       Impact factor: 9.910

6.  Targeted Next-Generation Sequencing Analysis of 1,000 Individuals with Intellectual Disability.

Authors:  Detelina Grozeva; Keren Carss; Olivera Spasic-Boskovic; Maria-Isabel Tejada; Jozef Gecz; Marie Shaw; Mark Corbett; Eric Haan; Elizabeth Thompson; Kathryn Friend; Zaamin Hussain; Anna Hackett; Michael Field; Alessandra Renieri; Roger Stevenson; Charles Schwartz; James A B Floyd; Jamie Bentham; Catherine Cosgrove; Bernard Keavney; Shoumo Bhattacharya; Matthew Hurles; F Lucy Raymond
Journal:  Hum Mutat       Date:  2015-09-30       Impact factor: 4.878

7.  Prevalence and architecture of de novo mutations in developmental disorders.

Authors: 
Journal:  Nature       Date:  2017-01-25       Impact factor: 49.962

8.  Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia.

Authors:  J Tarabeux; O Kebir; J Gauthier; F F Hamdan; L Xiong; A Piton; D Spiegelman; É Henrion; B Millet; F Fathalli; R Joober; J L Rapoport; L E DeLisi; É Fombonne; L Mottron; N Forget-Dubois; M Boivin; J L Michaud; P Drapeau; R G Lafrenière; G A Rouleau; M-O Krebs
Journal:  Transl Psychiatry       Date:  2011-11-15       Impact factor: 6.222

9.  De novo mutations in epileptic encephalopathies.

Authors:  Andrew S Allen; Samuel F Berkovic; Patrick Cossette; Norman Delanty; Dennis Dlugos; Evan E Eichler; Michael P Epstein; Tracy Glauser; David B Goldstein; Yujun Han; Erin L Heinzen; Yuki Hitomi; Katherine B Howell; Michael R Johnson; Ruben Kuzniecky; Daniel H Lowenstein; Yi-Fan Lu; Maura R Z Madou; Anthony G Marson; Heather C Mefford; Sahar Esmaeeli Nieh; Terence J O'Brien; Ruth Ottman; Slavé Petrovski; Annapurna Poduri; Elizabeth K Ruzzo; Ingrid E Scheffer; Elliott H Sherr; Christopher J Yuskaitis; Bassel Abou-Khalil; Brian K Alldredge; Jocelyn F Bautista; Samuel F Berkovic; Alex Boro; Gregory D Cascino; Damian Consalvo; Patricia Crumrine; Orrin Devinsky; Dennis Dlugos; Michael P Epstein; Miguel Fiol; Nathan B Fountain; Jacqueline French; Daniel Friedman; Eric B Geller; Tracy Glauser; Simon Glynn; Sheryl R Haut; Jean Hayward; Sandra L Helmers; Sucheta Joshi; Andres Kanner; Heidi E Kirsch; Robert C Knowlton; Eric H Kossoff; Rachel Kuperman; Ruben Kuzniecky; Daniel H Lowenstein; Shannon M McGuire; Paul V Motika; Edward J Novotny; Ruth Ottman; Juliann M Paolicchi; Jack M Parent; Kristen Park; Annapurna Poduri; Ingrid E Scheffer; Renée A Shellhaas; Elliott H Sherr; Jerry J Shih; Rani Singh; Joseph Sirven; Michael C Smith; Joseph Sullivan; Liu Lin Thio; Anu Venkat; Eileen P G Vining; Gretchen K Von Allmen; Judith L Weisenberg; Peter Widdess-Walsh; Melodie R Winawer
Journal:  Nature       Date:  2013-08-11       Impact factor: 49.962

10.  GRIN2A mutations cause epilepsy-aphasia spectrum disorders.

Authors:  Gemma L Carvill; Brigid M Regan; Simone C Yendle; Brian J O'Roak; Natalia Lozovaya; Nadine Bruneau; Nail Burnashev; Adiba Khan; Joseph Cook; Eileen Geraghty; Lynette G Sadleir; Samantha J Turner; Meng-Han Tsai; Richard Webster; Robert Ouvrier; John A Damiano; Samuel F Berkovic; Jay Shendure; Michael S Hildebrand; Pierre Szepetowski; Ingrid E Scheffer; Heather C Mefford
Journal:  Nat Genet       Date:  2013-08-11       Impact factor: 38.330

View more
  65 in total

1.  Three de novo DDX3X variants associated with distinctive brain developmental abnormalities and brain tumor in intellectually disabled females.

Authors:  Marcello Scala; Annalaura Torella; Mariasavina Severino; Giovanni Morana; Raffaele Castello; Andrea Accogli; Antonio Verrico; Maria Stella Vari; Gerarda Cappuccio; Michele Pinelli; Giuseppina Vitiello; Gaetano Terrone; Alessandra D'Amico; Vincenzo Nigro; Valeria Capra
Journal:  Eur J Hum Genet       Date:  2019-04-01       Impact factor: 4.246

2.  De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases.

Authors:  Jia Li; Jin Zhang; Weiting Tang; Ruth K Mizu; Hirofumi Kusumoto; Wenshu XiangWei; Yuchen Xu; Wenjuan Chen; Johansen B Amin; Chun Hu; Varun Kannan; Stephanie R Keller; William R Wilcox; Johannes R Lemke; Scott J Myers; Sharon A Swanger; Lonnie P Wollmuth; Slavé Petrovski; Stephen F Traynelis; Hongjie Yuan
Journal:  Hum Mutat       Date:  2019-09-10       Impact factor: 4.878

3.  Phenotypic Spectrum and Severity of Disease Depending on the Mutated Protein Domain of NMDA Receptor-Encoding Genes.

Authors:  Martin Poot
Journal:  Mol Syndromol       Date:  2019-04-12

4.  Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders.

Authors:  Weiting Tang; Ding Liu; Stephen F Traynelis; Hongjie Yuan
Journal:  Neuropharmacology       Date:  2020-07-24       Impact factor: 5.250

5.  Early-Life Epilepsies and the Emerging Role of Genetic Testing.

Authors:  Anne T Berg; Jason Coryell; Russell P Saneto; Zachary M Grinspan; John J Alexander; Mariana Kekis; Joseph E Sullivan; Elaine C Wirrell; Renée A Shellhaas; John R Mytinger; William D Gaillard; Eric H Kossoff; Ignacio Valencia; Kelly G Knupp; Courtney Wusthoff; Cynthia Keator; William B Dobyns; Nicole Ryan; Tobias Loddenkemper; Catherine J Chu; Edward J Novotny; Sookyong Koh
Journal:  JAMA Pediatr       Date:  2017-09-01       Impact factor: 16.193

6.  Mutations in SCN3A cause early infantile epileptic encephalopathy.

Authors:  Tariq Zaman; Ingo Helbig; Ivana Babić Božović; Suzanne D DeBrosse; A Christina Bergqvist; Kimberly Wallis; Livija Medne; Aleš Maver; Borut Peterlin; Katherine L Helbig; Xiaohong Zhang; Ethan M Goldberg
Journal:  Ann Neurol       Date:  2018-03-30       Impact factor: 10.422

7.  De Novo Variants in GRIA4 Lead to Intellectual Disability with or without Seizures and Gait Abnormalities.

Authors:  Sonja Martin; Adam Chamberlin; Deepali N Shinde; Maja Hempel; Tim M Strom; Allison Schreiber; Jessika Johannsen; Lilian Bomme Ousager; Martin J Larsen; Lars Kjaersgaard Hansen; Ali Fatemi; Julie S Cohen; Johannes Lemke; Kristina P Sørensen; Katherine L Helbig; Davor Lessel; Rami Abou Jamra
Journal:  Am J Hum Genet       Date:  2017-12-07       Impact factor: 11.025

8.  De Novo Mutations and Rare Variants Occurring in NMDA Receptors.

Authors:  Wenshu XiangWei; Yuwu Jiang; Hongjie Yuan
Journal:  Curr Opin Physiol       Date:  2017-12-27

9.  Hodgkin-Huxley-Katz Prize Lecture: Genetic and pharmacological control of glutamate receptor channel through a highly conserved gating motif.

Authors:  Riley E Perszyk; Scott J Myers; Hongjie Yuan; Alasdair J Gibb; Hiro Furukawa; Alexander I Sobolevsky; Stephen F Traynelis
Journal:  J Physiol       Date:  2020-06-15       Impact factor: 5.182

10.  Developmental Predictors of Cognitive and Adaptive Outcomes in Genetic Subtypes of Autism Spectrum Disorder.

Authors:  Anne B Arnett; Jennifer S Beighley; Evangeline C Kurtz-Nelson; Kendra Hoekzema; Tianyun Wang; Raphe A Bernier; Evan E Eichler
Journal:  Autism Res       Date:  2020-09-12       Impact factor: 5.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.